All In Biotech

Drug Trial Radar · NCT01720667

Efficacy of Intravenous Levetiracetam in Neonatal Seizures

Efficacy of Intravenous Levetiracetam in Neonatal Seizures: A Phase 2 Randomized Blinded Controlled Study of the Efficacy of Intravenous Levetiracetam (LEV) as First Line Treatment for Neonatal Seizures

Last checked: Nov 19, 2026Latest source record: Aug 21, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 280 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

280

Actual

Start

Mar 2013

Primary completion

Oct 31, 2017

Study completion Jul 31, 2019

Sponsor

Lead sponsor
Richard H. HaasAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of California, San Diego; Rady Children's Hospital, San Diego; Auckland City Hospital; Sharp Mary Birch Hospital for Women & Newborns; UCSF Benioff Children's Hospital Oakland; Food and Drug Administration (FDA)
First posted
Nov 2, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 15 minutes, up to 14 days
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A new anticonvulsant, levetiracetam will be studied to treat seizures in newborn infants. Current treatments for the brain damaging complication of neonatal seizures are unsatisfactory. Monitoring for seizure detection will be tested at five (5) US sites and one (1) international site using the internet.

Conditions

  • Neonatal Seizures

Interventions

  • Intravenous levetiracetamDrug

    Intravenous load of levetiracetam (40 to 60 mg/kg) following identification of EEG confirmed neonatal seizure.

  • Intravenous phenobarbitalDrug

    Intravenous load of phenobarbital (20 to 40 mg/kg) following EEG confirmation of seizure activity load.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Neonates With Seizure Cessation When Given Levetiracetam (40-60 mg/kg) as First Line Therapy Compared to Phenobarbital (20-40mg/kg)Time frame: 24 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California, San Diego Medical Center / Neonatal Intensive Care Unit (NICU)

    San Diego, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.